



ALL

IMAGES

VIDEOS

802,000 Results

Any time ▼

## Osteoporosis in liver disease: pathogenesis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892399>

Apr 06, 2016 · Treatment of viral liver disease associated osteoporosis appears to be a causal treatment geared to achieve **sustained suppression of hepatitis B virus replication or hepatitis C virus sustained viral response** [Arase et al. 2010]. It has been shown that the incidence of osteoporotic fractures in patients with hepatitis C is significantly reduced after successful ...

**Cited by:** 24

**Author:** Gabriela Handzlik-Orlik, Michał Holecki,...

**Publish Year:** 2016

## Denosumab Prevents Osteoporosis in Autoimmune Liver ...

<https://www.empr.com/.../denosumab-prevents-osteoporosis-in-autoimmune-liver-diseases> ▼

Nov 11, 2016 · BOSTON, MA—Injections **of denosumab** every 6 months prevent **osteoporosis** in **patients** with primary biliary cholangitis and autoimmune hepatitis, with minimal adverse **effects**...

**Author:** Bryant Furlow

## Effects of denosumab versus teriparatide in glucocorticoid ...

<https://www.sciencedirect.com/science/article/pii/S235218722030053X>

Our data suggest that teriparatide has better therapeutic **effects** than **denosumab** in GIO **patients** receiving bisphosphonates as pretreatment. Bone turnover markers have been used as a tool for monitoring **patients'** responses to **treatment** for **osteoporosis** (Eastell et al., 2018). Changes in bone turnover markers are associated with later changes in BMD.

## Efficacy and Safety of 3-Year Denosumab Therapy for ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30904>

Aug 20, 2019 · **Osteoporosis** is a major complication in **patients** with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). **Denosumab**, a fully human monoclonal antibody against the receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), increases bone mineral density (BMD) by inhibiting development and activity of osteoclasts and decreasing bone resorption.



ALL

IMAGES

VIDEOS

802,000 Results

Any time ▼

## Osteoporosis in liver disease: pathogenesis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892399>

Apr 06, 2016 · Treatment of viral liver disease associated osteoporosis appears to be a causal treatment geared to achieve **sustained suppression of hepatitis B virus replication or hepatitis C virus sustained viral response** [Arase et al. 2010]. It has been shown that the incidence of osteoporotic fractures in patients with hepatitis C is significantly reduced after successful ...

**Cited by:** 24

**Author:** Gabriela Handzlik-Orlik, Michał Holecki,...

**Publish Year:** 2016

## Denosumab Prevents Osteoporosis in Autoimmune Liver ...

<https://www.empr.com/.../denosumab-prevents-osteoporosis-in-autoimmune-liver-diseases> ▼

Nov 11, 2016 · BOSTON, MA—Injections of **denosumab** every 6 months prevent **osteoporosis** in **patients** with primary biliary cholangitis and autoimmune hepatitis, with minimal adverse **effects**...

**Author:** Bryant Furlow

## Effects of denosumab versus teriparatide in glucocorticoid ...

<https://www.sciencedirect.com/science/article/pii/S235218722030053X>

Our data suggest that teriparatide has better therapeutic **effects** than **denosumab** in GIO **patients** receiving bisphosphonates as pretreatment. Bone turnover markers have been used as a tool for monitoring **patients'** responses to **treatment** for **osteoporosis** (Eastell et al., 2018). Changes in bone turnover markers are associated with later changes in BMD.

## Efficacy and Safety of 3-Year Denosumab Therapy for ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30904>

Aug 20, 2019 · **Osteoporosis** is a major complication in **patients** with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). **Denosumab**, a fully human monoclonal antibody against the receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), increases bone mineral density (BMD) by inhibiting development and activity of osteoclasts and decreasing bone resorption.



**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 56760

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Study*

**Effects of denosumab treatment in chronic liver disease patients with osteoporosis**

Chisato Saeki, Mitsuru Saito, Tsunekazu Oikawa, Masanori Nakano, Yuichi Torisu,  
Masayuki Saruta, Akihito Tsubota

**Abstract**

**BACKGROUND**

Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease (CLD) patients. Denosumab has been shown to increase bone mineral density (BMD) and decrease the risk of osteoporotic fracture in the general population. However, there are few reports evaluating the efficacy of denosumab in CLD patients.

**Match Overview**

|   |  |     |
|---|--|-----|
| 1 | <b>Internet</b> 84 words<br>crawled on 14-Jul-2020<br><a href="http://link.springer.com">link.springer.com</a>   | 2%  |
| 2 | <b>Internet</b> 73 words<br>crawled on 31-Jul-2020<br><a href="http://www.mdpi.com">www.mdpi.com</a>   | 2%  |
| 3 | <b>Internet</b> 50 words<br>crawled on 28-May-2020<br><a href="http://bmcmusculoskeletdisord.biomedcentral.com">bmcmusculoskeletdisord.biomedcentral.com</a> | 1%  |
| 4 | <b>Internet</b> 29 words<br>crawled on 31-Oct-2010<br><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>   | 1%  |
| 5 | <b>Internet</b> 25 words<br>crawled on 21-Jul-2017<br><a href="http://ar.iiarjournals.org">ar.iiarjournals.org</a>   | 1%  |
| 6 | <b>Internet</b> 25 words<br>crawled on 11-May-2015<br><a href="http://toukastress.jp">toukastress.jp</a>   | 1%  |
| 7 | <b>Crossref</b> 20 words<br>Sakae Tanaka. "Role of RANKL in physiological and patho...<br>gical bone resorption and therapeutics targeting the RANKL         | <1% |
| 8 | <b>Internet</b> 18 words<br>crawled on 21-Mar-2019<br><a href="http://www.science.gov">www.science.gov</a>   | <1% |



ALL

IMAGES

VIDEOS

802,000 Results

Any time ▾

## Osteoporosis in liver disease: pathogenesis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892399>

Apr 06, 2016 · Pathologic fracture in **osteoporosis** significantly affects quality of life and life expectancy. By some estimates, 40% of **patients with chronic liver disease** may experience osteoporotic fracture. In this study we review the pathogenesis, diagnosis and **treatment** of specific **liver disease** entities and their relation to **osteoporosis**.

Cited by: 25

Author: Gabriela Handzlik-Orlik, Michał Holecki, ...

Publish Year: 2016

## Denosumab Prevents Osteoporosis in Autoimmune Liver ...

<https://www.empr.com/home/mpr-first-report/aasld...> ▾

Nov 11, 2016 · BOSTON, MA—Injections of **denosumab** every 6 months prevent **osteoporosis** in **patients** with primary biliary cholangitis and autoimmune hepatitis, with minimal adverse effects...

Author: Bryant Furrow

## Denosumab - LiverTox - NCBI Bookshelf

<https://www.ncbi.nlm.nih.gov/books/NBK548424>

Side effects of denosumab are uncommon, but can include injection site reactions, back and joint pains, rash, diarrhea, nausea and vomiting and headache. Rare side effects include **severe infusion reactions**, **hypersensitivity reactions**, **anaphylaxis**, **hypocalcemia**, **osteonecrosis of the jaw** and **atypical femoral fractures**.

### PEOPLE ALSO ASK

Can liver disease cause osteoporosis? ▾

How does osteoporosis affect the liver? ▾

Can denosumab be used for infection? ▾

Is denosumab metabolized by kidneys? ▾